Earlier studies have shown that estrogen possess protective function against the
development of pathological cardiac hypertrophy. However, the molecular mechanisms of …

Cardiovascular incidences are markedly higher in men than in pre-menstrual women.
However, this advantage in women declines with aging and therefore can be correlated with …

The present study was aimed to investigate the protective effects of 17β-estradiol (E2) and
estrogen receptor α (ERα) on isoproterenol (ISO)-treated H9c2 cardiomyoblast cells. In the …

Estrogen has been demonstrated to protect the heart against cardiac remodelling and heart
failure in women. G protein-coupled estrogen receptor 1 (GPER1) is a recently discovered …

Secretion of multifunctional estrogen and its receptor has been widely considered as the
reason for markedly higher frequency of heart disease in men than in women. 17β-Estradiol …

This study was designed to determine the effects of 17β-estradiol (E2) in overcoming the
cardiac over-loading and cardiac fibrosis in rats. E2 (100 ng/kg) or oil was applied in female …

Clinical and experimental studies have established that gender is a factor in the
development of ventricular hypertrophy. We investigated whether the attenuated …

Cardiac hypertrophy, one of the major risk factors in hypertension, is associated with a high
incidence of congestive heart failure and sudden death. Despite efforts over the last 20 …

Cardiac hypertrophy is a common pathological alteration in heart disease, which has been
reported to be connected with serine/threonine protein phosphatases that control the …

Abstract Background/Aims: 17β-estradiol (17βE2) plays an important cardiovascular role by
activating estrogen receptors (ER) α and ERβ. Previous studies demonstrated that the novel …